Data and code from: Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer’s disease

Identifying plasma-based biomarkers that can accurately differentiate Lewy body disease (LBD) from Alzheimer’s disease (AD) remains a major challenge. Extracellular vesicles (EVs), which carry molecular cargo from their parent cells and can cross the blood-brain barrier, offer a new path forward. We developed the multiplexed Track-Etch magnetic NanoPOre (mTENPO) platform, a highly parallelized microfluidic technology for cell-specific EV isolation, and demonstrated independent enrichment of GluR2+ (neuron-derived) and GLAST+ (astrocyte-derived) EVs from the antemortem plasma of 137 autopsy-confirmed LBD, AD, mixed pathology, and control subjects. By integrating miRNA sequencing of GluR2+ and GLAST+ EV cargo with plasma measurements of Aβ40, Aβ42, tau, p-Tau181, and p-Tau231, we identified a multimodal 15-feature panel that more comprehensively reflects brain pathology than conventional biomarkers. Using 10-fold cross-validation to mitigate overfitting, the panel achieved an accuracy of..., All participants or their proxies provided informed consent for this analysis. Individual identifiers and demographic information have been removed to protect patient privacy., , # Data and code from: Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer’s disease

Dataset DOI: [10.5061/dryad.612jm64j4](10.5061/dryad.612jm64j4)

## Description of the data and file structure

We analyzed plasma from N = 137 pathologically confirmed Lewy body disease (LBD), Alzheimer's disease (AD), combined AD/LBD, AD with amygdala Lewy bodies (AD/ALB), and control subjects. We performed neuron-derived (GluR2+) or astrocyte-derived (GLAST+) EV enrichment using our lab's multiplexed Track-Etch magnetic NanoPOre (mTENPO) sorting platform, followed by next-generation sequencing to analyze their miRNA cargo. We also performed gold-standard digital enzyme-linked immunosorbent assay (ELISA) to determine Aβ40, Aβ42, tau, p-Tau181, p-Tau231 expression. Using GluR2+ EV miRNA, GLAST+ EV miRNA, and plasma protein expression, we applied feature selection and 10-fold cross-validation to find biomarker panels that c...,